PMID- 24926284
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140613
LR  - 20211021
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 5
DP  - 2014
TI  - Behavioral and neurophysiological effects of transdermal rotigotine in atypical 
      parkinsonism.
PG  - 85
LID - 10.3389/fneur.2014.00085 [doi]
LID - 85
AB  - Effective therapies for the so-called atypical parkinsonian syndrome (APS) such 
      as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or 
      corticobasal syndrome (CBS) are not available. Dopamine agonists (DA) are not 
      often used in APS because of inefficacy and in a minority of case, their side 
      effects, like dyskinesias, impairment of extrapyramidal symptoms or the 
      appearance of psychosis, and REM sleep behavioral disorders (RBD). Transdermal 
      rotigotine (RTG) is a non-ergot dopamine agonist indicated for use in early and 
      advanced Parkinson's disease with a good tolerability and safety. Moreover, its 
      action on a wide range of dopamine receptors, D1, D2, D3, unlike other DA, could 
      make it a good option in APS, where a massive dopamine cell loss is documented. 
      In this pilot, observational open-label study we evaluate the efficacy and 
      tolerability of RTG in patients affected by APS. Thirty-two subjects with 
      diagnosis of APS were treated with transdermal RTG. APS diagnosis was: MSA 
      parkinsonian type (MSA-P), MSA cerebellar type (MSA-C), PSP, and CBS. Patients 
      were evaluated by UPDRS-III, neuropsychiatric inventory, mini mental state 
      examination at baseline, and after 6, 12, and 18 months. The titration schedule 
      was maintained very flexible, searching the major clinical effect and the minor 
      possible adverse events (AEs) at each visit. AEs were recorded. APS patients 
      treated with RTG show an overall decrease of UPDRS-III scores without increasing 
      behavioral disturbances. Only three patients were dropped out of the study. Main 
      AEs were hypotension, nausea, vomiting, drowsiness, and tachycardia. The 
      electroencephalographic recording power spectra analysis shows a decrease of 
      theta and an increase of low alpha power. In conclusion, transdermal RTG seems to 
      be effective and well tolerated in APS patients.
FAU - Moretti, Davide Vito
AU  - Moretti DV
AD  - IRCCS San Giovanni di Dio Fatebenefratelli , Brescia , Italy.
FAU - Binetti, Giuliano
AU  - Binetti G
AD  - IRCCS San Giovanni di Dio Fatebenefratelli , Brescia , Italy.
FAU - Zanetti, Orazio
AU  - Zanetti O
AD  - IRCCS San Giovanni di Dio Fatebenefratelli , Brescia , Italy.
FAU - Frisoni, Giovanni Battista
AU  - Frisoni GB
AD  - IRCCS San Giovanni di Dio Fatebenefratelli , Brescia , Italy.
LA  - eng
PT  - Journal Article
DEP - 20140605
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC4046164
OTO - NOTNLM
OT  - atypical parkinsonism
OT  - efficacy
OT  - open-label study
OT  - rotigotine
OT  - safety
EDAT- 2014/06/14 06:00
MHDA- 2014/06/14 06:01
PMCR- 2014/06/05
CRDT- 2014/06/14 06:00
PHST- 2013/11/12 00:00 [received]
PHST- 2014/05/16 00:00 [accepted]
PHST- 2014/06/14 06:00 [entrez]
PHST- 2014/06/14 06:00 [pubmed]
PHST- 2014/06/14 06:01 [medline]
PHST- 2014/06/05 00:00 [pmc-release]
AID - 10.3389/fneur.2014.00085 [doi]
PST - epublish
SO  - Front Neurol. 2014 Jun 5;5:85. doi: 10.3389/fneur.2014.00085. eCollection 2014.